Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms

Psychopharmacology
Olivia FrånbergT H Svensson

Abstract

Asenapine, a psychopharmacologic agent developed for schizophrenia and bipolar disorder, has higher affinity for 5-HT(2A/C,6,7) and alpha(2) adrenergic receptors than for D(2) receptors. Asenapine exhibits potent antipsychotic-like effects without inducing catalepsy, increases cortical and subcortical dopamine release, and facilitates cortical glutamatergic transmission in rats. In this study, we further analyzed the effects of asenapine on dopaminergic, noradrenergic, and serotonergic systems in the rat brain. We studied the effects of asenapine on (1) dopaminergic neurons in the ventral tegmental area (VTA) and noradrenergic neurons in the locus coeruleus using in vivo single cell recording, (2) release of dopamine and noradrenaline (medial prefrontal cortex), serotonin (frontal cortex), and dopamine (nucleus accumbens), using in vivo microdialysis. Systemic asenapine increased dopaminergic (0.001-0.2 mg/kg, i.v.) and noradrenergic (0.025-0.05 mg/kg i.v.) neuronal firing, and asenapine (0.1-0.2 mg/kg, s.c) increased cortical noradrenaline and serotonin output. Local asenapine administration increased all three monoamines in the cortex but did not affect accumbal dopamine output. Intra-VTA tetrodotoxin perfusion blocked asenap...Continue Reading

References

Aug 2, 2012·Expert Opinion on Pharmacotherapy·Frank I Tarazi, Stephen M Stahl
Aug 2, 2014·Expert Opinion on Drug Safety·Bernardo Dell'OssoAlfredo Carlo Altamura
Apr 13, 2012·Clinical Therapeutics·Steven C Stoner, Heather A Pace
Mar 16, 2011·CNS Neuroscience & Therapeutics·Thomas L Schwartz, Stephen M Stahl
Feb 7, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Chris A OosterhofPierre Blier
Feb 5, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Andrea de BartolomeisC Tomasetti
Oct 25, 2012·Neuroscience and Biobehavioral Reviews·Ulrich Hegerl, Tilman Hensch
Sep 13, 2011·The International Journal of Neuropsychopharmacology·Franck ChenuPierre Blier
Jun 22, 2012·The International Journal of Neuropsychopharmacology·Stella MantaPierre Blier
Jun 28, 2016·Expert Opinion on Drug Safety·L OrsoliniD De Berardis
Mar 29, 2013·Journal of Psychopharmacology·Leonardo CorteseSergey N Mosolov
Apr 22, 2016·Acta Neuropsychiatrica·Masayo OhyamaTsukasa Koyama
Apr 28, 2010·Expert Review of Neurotherapeutics·Roger S McIntyre
Sep 26, 2012·Clinical Schizophrenia & Related Psychoses·Nobumi MiyakeL Fredrik Jarskog
Aug 20, 2009·CNS Drugs·Juliane Weber, Paul L McCormack
Apr 19, 2017·CNS Neuroscience & Therapeutics·Sarah DelcourteNasser Haddjeri
Aug 8, 2015·Journal of Clinical Psychopharmacology·Edoardo Giuseppe OstinelliArmando D'Agostino

Citations

Oct 1, 1976·European Journal of Pharmacology·D W Gallager, G K Aghajanian
Jan 1, 1979·Pharmacology, Biochemistry, and Behavior·M SoutoH Altier
Mar 1, 1990·Pharmacology, Biochemistry, and Behavior·B CostallD M Tomkins
Jun 8, 1989·European Journal of Pharmacology·J Grenhoff, T H Svensson
Nov 1, 1986·Acta Physiologica Scandinavica·J GrenhoffT H Svensson
Jul 30, 1984·Brain Research·T G Dinan, G Aston-Jones
Mar 16, 1993·European Journal of Pharmacology·J Grenhoff, T H Svensson
Aug 1, 1993·Journal of Clinical Psychopharmacology·R E LitmanD Pickar
May 1, 1996·The British Journal of Psychiatry : the Journal of Mental Science·R E LitmanD Pickar
Aug 20, 1996·Proceedings of the National Academy of Sciences of the United States of America·M LaruelleR B Innis
Mar 1, 1996·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M M MarcusT H Svensson
Nov 1, 1996·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M G WadenbergS Ahlenius
Jul 1, 1997·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·P HertelT H Svensson
Feb 12, 1998·Naunyn-Schmiedeberg's Archives of Pharmacology·A N SchoffelmeerA H Mulder
Jul 2, 1998·Journal of Neurochemistry·B K Yamamoto, S Novotney
Mar 19, 1999·European Journal of Pharmacology·M MelisG L Gessa
May 27, 1999·Molecular and Chemical Neuropathology·K A Skau, C G Triplett
Mar 17, 2000·Brain Research. Brain Research Reviews·P S Goldman-RakicG V Williams
Jun 29, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M M MarcusT H Svensson
Jul 8, 2000·Proceedings of the National Academy of Sciences of the United States of America·A Abi-DarghamM Laruelle

Related Concepts

Cortex Bone Disorders
Adrenal Cortex Diseases
Schizophrenia
Saphris
Serotonin Measurement
Neurons
Serotonin
Brain
Tetrodotoxin
Nerve Endings

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.